Free Trial
NASDAQ:MCRB

Seres Therapeutics (MCRB) Stock Price, News & Analysis

Seres Therapeutics logo
$12.35 -0.03 (-0.24%)
Closing price 04:00 PM Eastern
Extended Trading
$12.21 -0.14 (-1.13%)
As of 05:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Seres Therapeutics Stock (NASDAQ:MCRB)

Key Stats

Today's Range
$11.95
$12.75
50-Day Range
$6.77
$12.38
52-Week Range
$6.53
$30.60
Volume
90,045 shs
Average Volume
132,497 shs
Market Capitalization
$107.82 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$73.67
Consensus Rating
Reduce

Company Overview

Seres Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
72nd Percentile Overall Score

MCRB MarketRank™: 

Seres Therapeutics scored higher than 72% of companies evaluated by MarketBeat, and ranked 275th out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Seres Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.75, and is based on 1 buy rating, 1 hold rating, and 2 sell ratings.

  • Amount of Analyst Coverage

    Seres Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Seres Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Seres Therapeutics are expected to decrease in the coming year, from ($0.38) to ($0.56) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Seres Therapeutics is -2.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Seres Therapeutics is -2.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Seres Therapeutics has a P/B Ratio of 7.79. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Seres Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    10.55% of the float of Seres Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Seres Therapeutics has a short interest ratio ("days to cover") of 6.9.
  • Change versus previous month

    Short interest in Seres Therapeutics has recently decreased by 4.47%, indicating that investor sentiment is improving.
  • Dividend Yield

    Seres Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Seres Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    10.55% of the float of Seres Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Seres Therapeutics has a short interest ratio ("days to cover") of 6.9.
  • Change versus previous month

    Short interest in Seres Therapeutics has recently decreased by 4.47%, indicating that investor sentiment is improving.
  • News Sentiment

    Seres Therapeutics has a news sentiment score of 1.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Seres Therapeutics this week, compared to 2 articles on an average week.
  • Search Interest

    5 people have searched for MCRB on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Seres Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 4.70% of the stock of Seres Therapeutics is held by insiders.

  • Percentage Held by Institutions

    59.34% of the stock of Seres Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Seres Therapeutics' insider trading history.
Receive MCRB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Seres Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MCRB Stock News Headlines

Trump’s treachery
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
See More Headlines

MCRB Stock Analysis - Frequently Asked Questions

Seres Therapeutics' stock was trading at $16.62 at the start of the year. Since then, MCRB stock has decreased by 24.5% and is now trading at $12.54.

Seres Therapeutics, Inc. (NASDAQ:MCRB) issued its quarterly earnings results on Wednesday, May, 7th. The biotechnology company reported ($2.24) EPS for the quarter, missing analysts' consensus estimates of ($0.67) by $1.57.
Read the conference call transcript
.

Seres Therapeutics's stock reverse split before market open on Tuesday, April 22nd 2025.The 1-20 reverse split was announced on Thursday, April 10th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Monday, April 21st 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Seres Therapeutics (MCRB) raised $101 million in an initial public offering (IPO) on Friday, June 26th 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. Goldman Sachs and BofA Merrill Lynch acted as the underwriters for the IPO and Leerink Partners and Canaccord Genuity were co-managers.

Shares of MCRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Seres Therapeutics investors own include PayPal (PYPL), NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Micron Technology (MU), QUALCOMM (QCOM) and NIO (NIO).

Company Calendar

Last Earnings
5/07/2025
Today
7/10/2025
Next Earnings (Estimated)
8/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:MCRB
CIK
1609809
Fax
N/A
Employees
330
Year Founded
N/A

Price Target and Rating

High Price Target
$200.00
Low Price Target
$6.00
Potential Upside/Downside
+488.2%
Consensus Rating
Reduce
Rating Score (0-4)
1.75
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
($4.60)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$140 thousand
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-41,084.76%
Return on Assets
-55.87%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.11
Quick Ratio
2.11

Sales & Book Value

Annual Sales
$126.32 million
Price / Sales
0.87
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.61 per share
Price / Book
7.78

Miscellaneous

Outstanding Shares
8,730,000
Free Float
8,322,000
Market Cap
$109.34 million
Optionable
Optionable
Beta
2.75

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NASDAQ:MCRB) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners